Abstract: Venous thromboembolism (VTE) is associated with increased morbidity and mortality, decreased quality of life, and higher economic burden in patients with cancer. Currently, the treatment of VTE in patients with cancer is particularly challenging. For many years, low molecular weight heparin (LMWHs) has been the standard for the treatment of cancer-associated VTE. Recently, the introduction of new oral anticoagulants (NOACs) may offer an oral anticoagulant option for some patients with cancer-associated thrombosis (CAT) as a growing body of literature supports the use of NOACs in the setting of CAT. With the use of NOAC as a new option in the management of CAT, clinicians now face several choices for the individual cancer patient with VTE. We need a more in-depth understanding of the drug properties, efficacy and safety, economic analysis that allows us to choose the most appropriate treatment for each patient. In the review, we will present an overview of CAT management, discuss the available evidence, economic costs for NOACs in the treatment of CAT, and seek to provide the best range of treatments for cancer patients.

Keywords: new oral anticoagulants, low molecular weight heparin, venous thromboembolism, cancer-associated thrombosis, anticoagulants


中文翻译：

---

新型口服抗凝剂为患有静脉血栓栓塞的癌症患者开辟了新视野

摘要：静脉血栓栓塞症 (VTE) 与癌症患者的发病率和死亡率增加、生活质量下降和经济负担增加有关。目前，癌症患者 VTE 的治疗尤其具有挑战性。多年来，低分子量肝素 (LMWH) 一直是治疗癌症相关 VTE 的标准。最近，随着越来越多的文献支持在 CAT 环境中使用 NOAC，新的口服抗凝剂 (NOAC) 可能为一些癌症相关血栓形成 (CAT) 患者提供口服抗凝剂选择。随着使用 NOAC 作为 CAT 管理的新选择，临床医生现在面临着针对患有 VTE 的个体癌症患者的多种选择。我们需要更深入地了解药物的特性、功效和安全性，经济分析使我们能够为每位患者选择最合适的治疗方法。在这篇综述中，我们将概述 CAT 管理，讨论可用的证据、NOAC 治疗 CAT 的经济成本，并寻求为癌症患者提供最佳治疗范围。

关键词：新型口服抗凝剂 低分子肝素 静脉血栓栓塞 癌相关血栓形成 抗凝剂